Trial · NCT06369714
Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.
NCT06369714, Not applicable, Recruiting, Lei Lei, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. Trials, record NCT06369714. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06369714
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.
- NCT number
- NCT06369714
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 210 participants, estimated
- Lead sponsor
- Lei Lei, MD
- Conditions
- Attention Deficit Disorder With Hyperactivity, Executive Function Disorder
- Interventions
- Concerta, Digital therapeutics
- First posted
- 2024-04-17
- Last updated
- 2025-06-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Swanson, Nolan, and Pelham IV Rating Scale | Baseline to End of Treatment (Week 8) and to Follow-up (Week 20, Week 32) | The Swanson, Nolan, and Pelham IV Rating Scales (SNAP-IV) will be completed by parents to assess the severity of ADHD symptoms. The values range from 0 to 3, with lower scores indicating a better outcome. |
| Secondary | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for ADHD | Baseline to End of Treatment (Week 8) and to Follow-up (Week 20, Week 32) | The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for ADHD will be used to assess the number of core symptoms. There are a total of 18 core symptoms, with fewer symptoms indicating a better outcome. |
| Secondary | Questionnaire-Children with Difficulties | Baseline to End of Treatment (Week 8) and to Follow-up (Week 20, Week 32) | The Questionnaire-Children with Difficulties (QCD) will be completed by parents to assess the social abilities of participants. The total questionnaire score is 57, and a score below 30 suggests impaired functioning. |
| Secondary | Behavior Rating Inventory of Executive Function | Baseline to End of Treatment (Week 8) and to Follow-up (Week 20, Week 32) | The Behavior Rating Inventory of Executive Function (BRIEF) will be completed by parents to assess changes in executive function. The normal standards for scores vary by age, with lower scores indicating a better outcome. |
| Secondary | Continuous Performance Test | Baseline to End of Treatment (Week 8) and to Follow-up (Week 20, Week 32) | A newly designed Continuous Performance Test (CPT) will be administered to participants by investigators, with higher accuracy rates indicating a better outcome. |
| Secondary | Digital Cancellation Test | Baseline to End of Treatment (Week 8) and to Follow-up (Week 20, Week 32) | The Digit Cancellation Test (DCT) will be administered to participants by investigators, with higher scores indicating a better outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42152117 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Cancellation Test | Secondary outcome | ConductCognition |
| Continuous Performance Test | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06369714
GET https://conductscience.org/api/trials/v1/NCT06369714/registered